Search results
Results from the WOW.Com Content Network
R-HDAC, or R-HD-AraC (ituximab plus (H)igh (D)ose ra-) is a chemotherapy regimen that is used, alternating with R-Maxi-CHOP, as part of so-called "Nordic protocol" of treating mantle cell lymphoma. It consists of monoclonal antibody rituximab and high-dose antimetabolite cytarabine .
MOPP is a combination chemotherapy regimen used to treat Hodgkin lymphoma. The acronym is derived from the component drugs of the regimen: ustargen (also known as mechlorethamine, chlormethine, mustine, nitrogen mustard, or MSD) ncovin (also known as Vincristine or VCR) rocarbazine (also known as Matulane or Natulan)
DHAP in context of chemotherapy is an acronym for chemotherapy regimen that is used for remission induction in cases of relapsed or refractory non-Hodgkin lymphoma and Hodgkin's lymphoma. [1] It is usually given for 2-3 courses, then followed by high-dose chemotherapy and autologous stem cell transplantation .
EPOCH is an intensive chemotherapy regimen intended for treatment of aggressive non-Hodgkin's lymphoma. [1] [2] It is often combined with rituximab. In this case it is called R-EPOCH or EPOCH-R. The R-EPOCH regimen consists of: Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant;
ICE in the context of chemotherapy is an acronym for one of the chemotherapy regimens, used in salvage treatment of relapsed or refractory non-Hodgkin's lymphoma and Hodgkin lymphoma. In case of CD20-positive B cell lymphoid malignancies the ICE regimen is often combined today with rituximab. This regimen is then called ICE-R or R-ICE or RICE.
It was established as Clinical Lymphoma in 2000, renamed to Clinical Lymphoma & Myeloma in 2005 and obtained its current name in 2010. The journal covers research on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia, and related disorders, including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias.
The most common chemotherapy used for B-cell non-Hodgkin lymphoma is R-CHOP, which is a regimen of four drugs (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus rituximab. [ 33 ] R-CHP with polatuzumab vedotin , an antibody-drug conjugate, was included as a category 1 preferred regimen for first-line DLBCL by the National ...
Stanford V (usually spoken as Stanford Five), is a chemotherapy regimen (with accompanying Radiation therapy) intended as a first-line treatment for Hodgkin lymphoma.The regimen was developed in 1988, with the objective of maintaining a high remission rate while reducing the incidence of acute and long term toxicity, pulmonary damage, and sterility observed in alternative treatment regimens ...